Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358863 | 0.94 | KMT2A (0.54) | DDB1CRBNKMT2AMEN1NPSR1 | |
| SCHEMBL5355188 | 0.88 | KMT2A (0.51) | DDB1CRBNKMT2AMEN1NPSR1 | |
| SCHEMBL16661304 | 0.85 | DDB1 (0.56) | DDB1CRBNKMT2AALDH1A1MAPK1 | |
| SCHEMBL3028267 | 0.82 | DDB1 (0.46) | DDB1CRBNKMT2AMEN1NPSR1 | |
| SCHEMBL20599446 | 0.82 | ALDH1A1 (0.46) | DDB1CRBNKMT2AMEN1NPSR1 | |
| SCHEMBL18493339 | 0.82 | DDB1 (0.54) | DDB1CRBNKMT2AALDH1A1MAPK1 | |
| SCHEMBL7228727 | 0.81 | DDB1 (0.52) | DDB1CRBNKMT2AALDH1A1MAPK1 | |
| SCHEMBL7606349 | 0.80 | DDB1 (0.44) | DDB1CRBNKMT2AMEN1NPSR1 | |
| Fluoride SCHEMBL27773141 | 0.80 | ALDH1A1 (0.50) | DDB1CRBNALDH1A1 | |
| SCHEMBL1966881 | 0.80 | KMT2A (0.52) | DDB1CRBNKMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | DDB1 2333/4885CRBN 4750/4885KMT2A 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.